Time filter

Source Type

Ness Ziona, Israel

BiondVax | Date: 2014-04-28

An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X

BiondVax | Entity website

BiondVax Pharmaceuticals Ltd. Weizmann Science Park PO Box 4143, 14 Einstein Street Ness Ziona, 7403618, Israel

BiondVax | Entity website

Financial informationyardena2016-05-01T11:13:16+00:00 BiondVaxs Financial Reports and Results Please select from the links below to the financial reports with BiondVaxs quarterly and year-end financial results. Note that Biondvax only started reporting results in English from the first quarter of 2015 ...

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.0-1 | Award Amount: 7.82M | Year: 2013

UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 4 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of scientific and technological expertise from lead identification to clinical trial execution. UNISEC will bring a number of vaccine concepts together into a single study in order to identify, develop and clinically test the 3 most promising leads for a universal influenza vaccine, which must (1) demonstrate adequate (universal) protection, and (2) be technically suitable for development to a marketable product. Preclinical and clinical methodologies will be developed allowing a comparative evaluation of the vaccine concepts. Head-to-head comparisons in animal models will also be performed, with the most promising concepts to then be ready for clinical assessment. Independent comparative clinical studies will be executed and carried out by 5 established Clinical Trial Site partners. The expected impact of the UNISEC work programme will be the resolution of current problems of non-uniformity in the development and evaluation of universal influenza vaccines in Europe by a unified approach using an expert and sustainable vaccine expertise network. The UNISEC results will directly contribute to a timely, longer-term, broader, more effective and cost-effective universal influenza vaccine for the prevention of annual and pandemic influenza. The success of UNISEC will be based on the leading experience of its consortium partners; the proven track record of its clinical trial site partners; and a coherent and well-defined management structure and dissemination program, underpinned by the fact that several UNISEC partners were previously part of the successful EU FLUSECURE project.

Ben-Yedidia T.,BiondVax | Rudolph W.,BiondVax
Expert Review of Vaccines | Year: 2011

Interview by Paolo Reveglia, Assistant Commissioning Editor Tamar Ben-Yedidia has more than 15 years of experience in the field of immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd (Rehovot, Israel), working on the development of a recombinant hepatitis B vaccine. She joined the Weizmann Institute of Science (Rehovot, Israel) in 1994, and under the auspices of Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax (Ness Ziona, Israel). Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals. She received her PhD from the Weizmann Institute after completion of her doctoral thesis entitled 'A peptide-based vaccine against influenza'. Prior to joining BiondVax in October 2009, Wayne worked for 5 years as an Investment Banker. He worked for 4 years for Lehman Brothers in the Healthcare Investment Banking Group, mostly in London. After leaving Lehman Brothers as a Director in June 2008, Wayne joined UniCredit Markets and Investment Banking Division, and was based in their Tel Aviv office. Wayne holds an MBA from the Wharton School of the University of Pennsylvania (PA, USA). He is a Chartered Financial Analyst, and a qualified attorney in South Africa, and holds BCom and LLB degrees from the University of the Witwatersrand in Johannesburg, South Africa. © 2011 Expert Reviews Ltd. Source

Discover hidden collaborations